TTP and OS to the ≥2nd line cetuximab-containing treatment according to KRAS, BRAF, PIK3CA mutations status, PTEN protein expression, AREG and EREG mRNA expression and grade of skin rash in the KRAS WT patients′ population.
收藏数据链接：
官方服务：
资源简介：
*CI: Confidence Interval,#HR: Hazard Ration,∧WT: Wild Type,$Skin rash grade 2–3 vs. none,@Skin rash grade 2–3 vs. grade 1,&KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG downregulated,∞KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF mutant and EREG overexpressed,£KRAS or BRAF WT and EREG overexpressed vs. KRAS or BRAF WT EREG downregulated.
*置信区间（Confidence Interval），#风险比（Hazard Ratio，原文笔误为Hazard Ration），∧野生型（Wild Type），$2~3级皮肤皮疹 vs. 无皮肤皮疹，@2~3级皮肤皮疹 vs. 1级皮肤皮疹，&KRAS或BRAF野生型且EREG过表达 vs. KRAS或BRAF突变型且EREG下调，∞KRAS或BRAF野生型且EREG过表达 vs. KRAS或BRAF突变型且EREG过表达，£KRAS或BRAF野生型且EREG过表达 vs. KRAS或BRAF野生型且EREG下调
创建时间：
2015-12-02
